Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 100 /hr

★★★★★

☆☆☆☆☆

Hire Dr Balaji P.

India

USD 100 /hr

Medical Affairs Leader | 13+ Years in Neurology, Oncology & CNS | Evidence Generation, Phase II,IIITrials & KOL Strategy

Profile Summary

I am a Medical Affairs Leader with 13+ years of experience across India, Bangladesh, Sri Lanka, and Sub-Saharan Africa, specialising in Neurology, Oncology, CNS disorders, Sleep Medicine, Alzheimer’s Disease, and Metabolic Disorders. I have led medical strategy, executed major product launches, and driven evidence-generation initiatives including global Phase III and multiple Phase IV studies. My expertise spans clinical trial support, protocol development, scientific communication, publication strategy, real-world evidence generation, and KOL engagement. I have built and led high-performing medical teams, strengthened cross-functional collaboration, and partnered extensively with global and regional leaders. I bring a strong track record of translating complex science into clear, impactful insights for healthcare professionals, regulatory bodies, and commercial teams. With experience in Eisai, Biogen, UCB, and Wockhardt, I combine scientific depth with strategic execution to deliver high-quality medical solutions, patient-centric programs, and compliant medical affairs excellence.

Subject Matter Expertise

• ☆ Telecommunications
• ☆ Neurology
• ☆ Oncology
• ☆ Endocrinology
• ☆ Diabetes
• ☆ Healthcare Administration & Management
• ☆ Medical Affairs

Services

• Writing
• Research
• Consulting
• Product Development

Writing Clinical Trial Documentation, Medical Writing, Creative Writing, Newswriting

Research Feasibility Study, Gap Analysis, Scientific and Technical Research, Systematic Literature Review

Consulting Go-to-Market Strategy Consulting, Digital Strategy Consulting, Healthcare Consulting, Scientific and Technical Consulting

Product Development Formulation, Product Evaluation, Concept Development, Product Launch Support

Work Experience

Medical Director

Eisai Pharmaceuticals

December 2017 - Present

Education

MD

Datta Meghe Institute of Medical Sciences

April 2008 - April 2011

Certifications

• Royal College of Liverpool accredited Fellowship in Diabetes

  Medversity

  January 2025 - January 2025

Publications

JOURNAL ARTICLE

Ravat, Sangeeta, Rohatgi, Anshu, Kulkarni, Rahul, Jabeen, Shaik A, Patil, Balaji, Dash, Amitabh, Malhotra, Manoj(2024). Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged≥ 12 years for Treatment of focal-onset Epilepsy: Study 508. Epilepsia Open. 9. (3). p. 940. Wiley

Ravat, Sangeeta, Rohatgi, Anshu, Kulkarni, Rahul, Jabeen, Shaik A, Patil, Balaji, Dash, Amitabh, Malhotra, Manoj(2023). ESPRITE—E fficacy and S afety of adjunctive P erampanel in a prospective, R eal-world, Phase IV study in I ndian patients aged≥ 12 years for T reatment of focal-onset E pilepsy: Study 508. Epilepsia Open. Wiley Online Library

OTHER

Wechsler, Robert, Coppola, Antonietta, Rohatgi, Anshu, Patten, Anna, Goldman, Samantha, Gentile, Anna, Patil, Balaji, Dash, Amitabh, Ngo, Leock Y, Malhotra, Manoj(2022). 069 Real-world evidence on the safety and efficacy of adjunctive perampanel across different geographical regions. BMJ Publishing Group Ltd

CONFERENCE PAPER

Ravat, Sangeeta, Kulkarni, Rahul, Patil, Balaji, Dash, Amitabh, Malhotra, Manoj(2021). A phase IV, prospective, post-approval study of adjunctive perampanel in Indian patients aged>= 12 to< 18 years with focal-onset seizures: Study 508. EPILEPSIA. 62. p. 271--271.

Rohatgi, Anshu, Ravat, Sangeeta, Patil, Balaji, Dash, Amitabh, Malhotra, Manoj(2021). A phase IV, prospective, post-approval study of adjunctive perampanel in indian patients aged>= 12 Years with focal-onset seizures: Study 508. EPILEPSIA. 62. p. 48--48.

Ravat, Sangeeta, Kulkarni, Rahul, Rohatgi, Anshu, Ghosh, Pahari, Patil, Balaji, Dash, Amitabh, Malhotra, Manoj(2021). Study 508: A phase IV, post-approval study of adjunctive perampanel in Indian patients aged>= 12 years with epilepsy based on seizure type. EPILEPSIA. 62. p. 48--49.